Global levels of histone modifications predict prognosis in different cancers
- PMID: 19349354
- PMCID: PMC2671251
- DOI: 10.2353/ajpath.2009.080874
Global levels of histone modifications predict prognosis in different cancers
Abstract
Cancer cells exhibit alterations in histone modification patterns at individual genes and globally at the level of single nuclei in individual cells. We demonstrated previously that lower global/cellular levels of histone H3 lysine 4 dimethylation (H3K4me2) and H3K18 acetylation (ac) predict a higher risk of prostate cancer recurrence. Here we show that the cellular levels of both H3K4me2 and H3K18ac also predict clinical outcome in both lung and kidney cancer patients, with lower levels predicting significantly poorer survival probabilities in both cancer groups. We also show that lower cellular levels of H3K9me2, a modification associated with both gene activity and repression, is also prognostic of poorer outcome for individuals with either prostate or kidney cancers. The predictive power of these histone modifications was independent of tissue-specific clinicopathological variables, the proliferation marker Ki-67, or a p53 tumor suppressor mutation. Chromatin immunoprecipitation experiments indicated that the lower cellular levels of histone modifications in more aggressive cancer cell lines correlated with lower levels of modifications at DNA repetitive elements but not with gene promoters across the genome. Our results suggest that lower global levels of histone modifications are predictive of a more aggressive cancer phenotype, revealing a surprising commonality in prognostic epigenetic patterns of adenocarcinomas of different tissue origins.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671251/bin/zjh0050979970001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671251/bin/zjh0050979970002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671251/bin/zjh0050979970003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671251/bin/zjh0050979970004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671251/bin/zjh0050979970005.gif)
Similar articles
-
Global histone modification patterns predict risk of prostate cancer recurrence.Nature. 2005 Jun 30;435(7046):1262-6. doi: 10.1038/nature03672. Nature. 2005. PMID: 15988529
-
Histone modifications in cancer biology and prognosis.Prog Drug Res. 2011;67:91-106. doi: 10.1007/978-3-7643-8989-5_5. Prog Drug Res. 2011. PMID: 21141726 Review.
-
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.J Clin Oncol. 2010 Mar 10;28(8):1358-65. doi: 10.1200/JCO.2009.24.5639. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142597 Free PMC article.
-
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20841388
-
Towards the human cancer epigenome: a first draft of histone modifications.Cell Cycle. 2005 Oct;4(10):1377-81. doi: 10.4161/cc.4.10.2113. Epub 2005 Oct 20. Cell Cycle. 2005. PMID: 16205112 Review.
Cited by
-
Improved Mass Spectrometry-Based Methods Reveal Abundant Propionylation and Tissue-Specific Histone Propionylation Profiles.Mol Cell Proteomics. 2024 Jul;23(7):100799. doi: 10.1016/j.mcpro.2024.100799. Epub 2024 Jun 11. Mol Cell Proteomics. 2024. PMID: 38866077 Free PMC article.
-
Deciphering the Epigenetic Symphony of Cancer: Insights and Epigenetic Therapies Implications.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241250317. doi: 10.1177/15330338241250317. Technol Cancer Res Treat. 2024. PMID: 38780251 Free PMC article. Review.
-
Loss of hepatic Sirt7 accelerates diethylnitrosamine (DEN)-induced formation of hepatocellular carcinoma by impairing DNA damage repair.BMB Rep. 2024 Feb;57(2):98-103. doi: 10.5483/BMBRep.2023-0187. BMB Rep. 2024. PMID: 38303560 Free PMC article.
-
SIRT7 promotes Hippo/YAP activation and cancer cell proliferation in hepatocellular carcinoma via suppressing MST1.Cancer Sci. 2024 Apr;115(4):1209-1223. doi: 10.1111/cas.16091. Epub 2024 Jan 30. Cancer Sci. 2024. PMID: 38288904 Free PMC article.
-
Targeting drug-tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells.MedComm (2020). 2023 Aug 24;4(5):e342. doi: 10.1002/mco2.342. eCollection 2023 Oct. MedComm (2020). 2023. PMID: 37638338 Free PMC article. Review.
References
-
- Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107–116. - PubMed
-
- Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–153. - PubMed
-
- Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391:597–601. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous